Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam

References

• Ahonen J, Olkkola KT, Neuvonen PJ. 1996. The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundamental and Clinical Pharmacology 10:314–318.
   PubMed Web of Science ®Google Scholar
• Bourrie M, Meunier V, Berger Y, Fabre G. 1996. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 277:321–332.
   PubMed Web of Science ®Google Scholar
• Carlile DJ, Hakooz N, Bayliss MK, Houston JB. 1999. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. British Journal of Clinical Pharmacology 47:625–635.
   PubMed Web of Science ®Google Scholar
• Coller JK, Somogyi AA, Bochner F. 1999. Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4. Xenobiotica 29:973–986.
   PubMed Web of Science ®Google Scholar
• Dal Bo L, Verga F, Marzo A, La Commare P, De Vito ML. 1997. Gas chromatographic assay for estazolam in human plasma and results of a bioequivalence study. Pharmacological Research 35:329–333.
   Google Scholar
• Echizen H, Kawasaki H, Chiba K, Tani M, Ishizaki T. 1993. A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 264:1425–1431.
   PubMed Web of Science ®Google Scholar
• Giancarlo GM, Venkatakrishnan K, Granda BW, von Moltke LL, Greenblatt DJ. 2001. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. European Journal of Clinical Pharmacology 57:31–36.
   PubMed Web of Science ®Google Scholar
• Gorski JC, Jones DR, Hamman MA, Wrighton SA, Hall SD. 1999. Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica 29:931–944.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Miller LG, Shader RI. 1990. Neurochemical and pharmacokinetic correlates of the clinical action of benzodiazepine hypnotic drugs. The American Journal of Medicine 88:18s–24s.
   Google Scholar
• Greenblatt DJ, von Moltke LL, Harmatz JS, Ciraulo DA, Shader RI. 1993. Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. Journal of Clinical Psychiatry 54:4–11.
   PubMed Web of Science ®Google Scholar
• Greenblatt DJ, Wright CE, von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Couniharn M, Tobias S, Shader RI. 1998. Ketoconazole inhibition of triazolarn and alprazolam clearance: differential kinetic and dynamic consequences. Clinical Pharmacology and Therapeutics 64:237–247.
   PubMed Web of Science ®Google Scholar
• Halpert JR, Guengerich FP, Bend JR, Correia MA. 1994. Selective inhibitors of cytochromes P450. Toxicology and Applied Pharmacology 125:163–175.
   PubMed Web of Science ®Google Scholar
• Hesse LM, Venkatakrishnan K, von Moltke LL, Shader RI, Greenblatt DJ. 2001. CYP3A4 is the major GYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazeparn. Drug Metabolism and Disposition 29:133–140.
   PubMed Web of Science ®Google Scholar
• Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. 1997. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metabolism and Disposition 25:853–862.
   PubMed Web of Science ®Google Scholar
• Machinist JM, Bopp BA, Anderson DJ, Granneman GR, Sonders RC, Tolman K, Buchi K, Rollins D. 1986. Metabolism of 14C-estazolam in dogs and humans. Xenobiotica 16:11–20.
   PubMed Web of Science ®Google Scholar
• Miura M, Ohkubo T, Sugawara K, Okayama N, Otani K. 2002. Determination of estazolam in plasma by high-performance liquid chromatography with solid-phase extraction. Analytical Science 18:525–528.
   PubMed Web of Science ®Google Scholar
• Newton DJ, Wang RW, Lu AY. 1995. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition 23:154–158.
   Google Scholar
• Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Rance DJ, Wastall P. 1997. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. The Journal of Pharmacology and Experimental Therapeutics 283:46–58.
   PubMed Web of Science ®Google Scholar
• Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M. 1996. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 26:681–693.
   PubMed Web of Science ®Google Scholar
• Otsuji Y, Okuyarna N, Aoshima T, Fukasawa T, Kato K, Gerstenberg G, Miura M, Ohkubo T, Sugawara K, Otani K. 2002. No effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam. Therapeutic Drug Monitoring 24:375–378.
   PubMed Web of Science ®Google Scholar
• Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, Greenblatt DJ. 2000. Midazolarn and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. The Journal of Pharmacology and Experimental Therapeutics 292:618–628.
   PubMed Web of Science ®Google Scholar
• Phillips JP, Antal EJ, Smith RB. 1986. A pharmacokinetic drug interaction between erythromycin and triazolarn. The Journal of Clinical Psychopharmacology 6:297–299.
   PubMed Web of Science ®Google Scholar
• Pierce MW, Shu VS. 1990. Safety of estazolam. The United States clinical experience. The American Journal of Medicine 88:12S–17S.
   Google Scholar
• Rane A, Wilkinson GR, Shand DG. 1977. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. The Journal of Pharmacology and Experimental Therapeutics 200:420–424.
   PubMed Web of Science ®Google Scholar
• Shou M, Mei Q, Ettore Jr MW, Dai R, Baillie TA, Rushmore TH. 1999. Sigmoidal kinetic model for two cooperative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. The Biochemical Journal 340:845–853.
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Shader RI. 1998. Alprazolarn is another substrate for human cytochrome P450-3A isoforms. The Journal of Clinical Psychopharmacology 18:256.
   PubMed Web of Science ®Google Scholar
• Venkatakrishnan K, von Moltke LL, Greenblatt DJ. 2001. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. The Journal of Clinical Pharmacology 41:1149–1179.
   PubMed Web of Science ®Google Scholar
• Wilkinson GR, Shand DG. 1975. Commentary: a physiological approach to hepatic drug clearance. Clinical Pharmacology and Therapeutics 18:377–390.
   PubMed Web of Science ®Google Scholar
• von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI. 1996. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. The Journal of Pharmacology and Experimental Therapeutics 276:370–379.
   PubMed Web of Science ®Google Scholar
• Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K. 1998. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolarn. Psychopharmacology 139:269–272.
   PubMed Web of Science ®Google Scholar
• Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Chiba K, Ishizaki T. 1996. A kinetic and dynamic study of oral alprazolarn with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolarn metabolism. Clinical Pharmacology and Therapeutics 59:514–519.
   PubMed Web of Science ®Google Scholar
• Yuan R, Flockhart DA, Balian JD. 1999. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolarn, midazolarn, and triazolarn. The Journal of Clinical Pharmacology 39:1109–1125.
   PubMed Web of Science ®Google Scholar